My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Incyte Corporation - Common Stock (NQ:INCY)

102.69 +5.38 (+5.53%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

24 25 Next >

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 07, 2025

From Incyte

Via Business Wire

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

April 07, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst...

Via StockStory

Topics Artificial Intelligence

Meta, AMD, Apple, AT&T Among Biggest US Tech Giants That 'May Suffer The Most' As Tariffs Spark Trade Turmoil: Here's Why ↗

April 03, 2025

Tariffs could heavily impact top tech beneficiaries of globalization as the cost of the goods sold by these firms may rise.

Via Benzinga

Incyte Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) ↗

March 11, 2025

Via Benzinga

3 Reasons INCY is Risky and 1 Stock to Buy Instead

April 01, 2025

Over the past six months, Incyte’s shares (currently trading at $60.02) have posted a disappointing 11.8% loss while the S&P 500 was down 1.7%. This was partly driven by its softer quarterly results...

Via StockStory

Topics Stocks

XPeng, Reddit And Micron Tech Are Among Top 10 Large-Cap Losers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? ↗

March 23, 2025

Large-cap stocks worst performers last week, including BEKE, RDDT, FUTU, JHX, INCY, NUE, BAH, XPEV, MRNA, TU, WLK. Are they in your portfolio?

Via Benzinga

What's going on in today's session: S&P500 movers ↗

March 21, 2025

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.

Via Chartmill

Why Incyte Stock Was Tanking This Week ↗

March 21, 2025

Via The Motley Fool

1 Healthcare Stock on Our Watchlist and 2 to Brush Off

March 21, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID...

Via StockStory

Topics Stocks

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

March 20, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.

Via StockStory

Topics Artificial Intelligence

Tesla To $320? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 18, 2025

Via Benzinga

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

March 18, 2025

Via Benzinga

What's going on in today's after hours session: S&P500 movers ↗

March 17, 2025

As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.

Via Chartmill

Stay informed with the top movers within the S&P500 index on Monday. ↗

March 17, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.

Via Chartmill

Uncover the latest developments among S&P500 stocks in today's session. ↗

March 17, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Why Incyte (INCY) Stock Is Nosediving

March 17, 2025

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment, which fell...

Via StockStory

Gapping S&P500 stocks in Monday's session ↗

March 17, 2025

Let's have a look at what is happening on the US markets on Monday. Below you can find the S&P500 gap up and gap down stocks in today's session.

Via Chartmill

These S&P500 stocks are moving in today's pre-market session ↗

March 17, 2025

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.

Via Chartmill

Which stocks are moving before the opening bell on Monday? ↗

March 17, 2025

The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls ↗

March 17, 2025

Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and a well-tolerated safety profile.

Via Benzinga

Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive' ↗

March 17, 2025

Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as shares fell.

Via Investor's Business Daily

Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 17, 2025

Via Benzinga

Don't overlook INCYTE CORP (NASDAQ:INCY)—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

March 17, 2025

Take a closer look at INCYTE CORP , a remarkable value stock. NASDAQ:INCY excels in fundamentals and maintains a very reasonable valuation.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 17, 2025

Via Benzinga

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗

March 17, 2025

Via Benzinga

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

March 17, 2025

From Incyte

Via Business Wire

Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss ↗

March 11, 2025

Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results comparable to adults at 52 weeks.

Via Benzinga

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps ↗

March 10, 2025

Incyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary endpoint fell short.

Via Benzinga

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

March 08, 2025

From Incyte

Via Business Wire

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 07, 2025

From Incyte

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.